FDA expands labels for J&J’s Imaavy and Jazz’s Ziihera; Teva under Turkish antitrust probe

The U.S. Food and Drug Administration has broadened the approved uses for Johnson & Johnson’s oncology drug Imaavy and Jazz Pharmaceuticals’ Ziihera, adding new indications to each label.

These label expansions allow the drugs to be prescribed for additional patient populations, potentially increasing their market reach and offering more treatment options.

Separately, Turkish authorities have opened an antitrust investigation into Teva Pharmaceutical Industries, focusing on the company’s recent patent‑related activities in the country.

The probe could lead to regulatory actions or fines, depending on the findings of the investigation.